SV2010003704A - MODIFIED POLIPEPTIDES OF FACTOR IX AND USES OF THE SAME - Google Patents

MODIFIED POLIPEPTIDES OF FACTOR IX AND USES OF THE SAME

Info

Publication number
SV2010003704A
SV2010003704A SV2010003704A SV2010003704A SV2010003704A SV 2010003704 A SV2010003704 A SV 2010003704A SV 2010003704 A SV2010003704 A SV 2010003704A SV 2010003704 A SV2010003704 A SV 2010003704A SV 2010003704 A SV2010003704 A SV 2010003704A
Authority
SV
El Salvador
Prior art keywords
factor
modified
polipeptides
same
polypeptides
Prior art date
Application number
SV2010003704A
Other languages
Spanish (es)
Inventor
Alan Brooks
John E Murphy
Marian Seto
Xiaoqiao Jiang
Chandra Patel
Uwe Gritzan
Kornelia Kirchner
Ulrich Haupts
Original Assignee
Bayer Healthcare Llc
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc, Bayer Schering Pharma Ag filed Critical Bayer Healthcare Llc
Publication of SV2010003704A publication Critical patent/SV2010003704A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE DIVULGAN POLIPÉPTIDOS MODIFICADOS DEL FACTOR IX, TALES COMO LOS POLIPÉPTIDOS DEL FACTOR IX CON UNO O MÁS SITIOS DE GLICOSILACIÓN INTRODUCIDOS. LOS POLIPÉPTIDOS MODIFICADOS DEL FACTOR IX PUEDEN EXHIBIR UN INCREMENTO DE LA ESTABILIDAD IN VITRO O IN VIVO, TAL COMO UNA SEMIVIDA PLASMÁTICA MAS PROLONGADA. ASIMISMO SE DIVULGAN PROCEDIMIENTOS DE FABRICAR POLIPÉPTIDOS MODIFICADOS DEL FACTOR IX Y A PROCEDIMIENTOS DE USAR MODIFICADOS DEL FACTOR IX PARA, POR EJEMPLO, TRATAR A PACIENTES AFECTADOS POR HEMOFILIA BMODIFIED FACTOR IX POLYPEPTIDES ARE DISCLOSED, SUCH AS THE FACTOR IX POLYPEPTIDES WITH ONE OR MORE INTRODUCED GLYCOSILATION SITES. MODIFIED POLIPEPTIDES OF FACTOR IX MAY EXHIBIT AN INCREASE OF STABILITY IN VITRO OR IN VIVO, SUCH AS A MOST PROLONGED PLASMATIC SEMIVIDE. Likewise, PROCEDURES FOR MANUFACTURING MODIFIED POLIPEPTIDES OF FACTOR IX ARE DISCLOSED AND PROCEDURES FOR USING MODIFIED FACTOR IX FOR, FOR EXAMPLE, TREATING PATIENTS AFFECTED BY HEMOPHILIA B

SV2010003704A 2008-04-16 2010-10-15 MODIFIED POLIPEPTIDES OF FACTOR IX AND USES OF THE SAME SV2010003704A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12456708P 2008-04-16 2008-04-16
US4596108P 2008-04-17 2008-04-17

Publications (1)

Publication Number Publication Date
SV2010003704A true SV2010003704A (en) 2011-02-21

Family

ID=41265284

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2010003704A SV2010003704A (en) 2008-04-16 2010-10-15 MODIFIED POLIPEPTIDES OF FACTOR IX AND USES OF THE SAME

Country Status (17)

Country Link
EP (1) EP2288622A4 (en)
JP (1) JP2011517951A (en)
KR (1) KR20110005862A (en)
CN (1) CN102083856A (en)
AU (1) AU2009244633A1 (en)
BR (1) BRPI0910702A2 (en)
CA (1) CA2721683A1 (en)
CO (1) CO6311000A2 (en)
CR (1) CR11737A (en)
DO (1) DOP2010000311A (en)
EC (1) ECSP10010551A (en)
IL (1) IL208718A0 (en)
MX (1) MX2010011345A (en)
RU (1) RU2010146387A (en)
SG (1) SG189790A1 (en)
SV (1) SV2010003704A (en)
WO (1) WO2009137254A2 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2084274A2 (en) * 2006-06-19 2009-08-05 Nautilus Technology LLC Modified coagulation factor ix polypeptides and use thereof for treatment
JP5613876B2 (en) * 2007-10-15 2014-10-29 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル Human factor IX variants with extended half-life
DK3581650T3 (en) 2008-09-15 2023-03-13 Uniqure Biopharma B V FACTOR IX POLYPEPTIDE MUTANT, USE THEREOF AND A PROCEDURE FOR MANUFACTURE THEREOF
UA115120C2 (en) 2010-07-09 2017-09-25 Байоджен Хемофіліа Інк. Factor ix polypeptides and methods fo use thereof
AU2013204511B2 (en) * 2010-11-03 2016-03-17 Gc Biopharma Corp. Modified factor ix polypeptides and uses thereof
TWI557135B (en) 2010-11-03 2016-11-11 介控生化科技公司 Modified factor ix polypeptides and uses thereof
EP3527218A1 (en) 2011-06-10 2019-08-21 Bioverativ Therapeutics Inc. Pro-coagulant compounds and methods of use thereof
US10656167B2 (en) 2011-07-25 2020-05-19 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
JP5967631B2 (en) * 2012-04-27 2016-08-10 学校法人日本大学 Treatment for epithelial and endothelial damage
US10001495B2 (en) 2012-07-25 2018-06-19 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
WO2014052490A1 (en) 2012-09-25 2014-04-03 Biogen Idec Ma Inc. Methods of using fix polypeptides
EP2908847B1 (en) 2012-10-18 2022-03-30 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
DK3889173T3 (en) 2013-02-15 2023-10-09 Bioverativ Therapeutics Inc OPTIMIZED FACTOR VIII GENE
UY35463A (en) 2013-03-15 2014-10-31 Biogen Idec Inc FC-FACTOR IX POLYPEPTIDE FORMULATIONS IX.
HUE057005T2 (en) 2013-09-25 2022-04-28 Bioverativ Therapeutics Inc On-column viral inactivation methods
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
US10325687B2 (en) 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
JP2017500017A (en) 2013-12-20 2017-01-05 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
KR102385372B1 (en) 2014-03-24 2022-04-11 바이오버라티브 테라퓨틱스 인크. Lyophilized factor ix formulations
WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
AU2016301303B2 (en) 2015-08-03 2021-10-07 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
PT3411478T (en) 2016-02-01 2022-09-13 Bioverativ Therapeutics Inc Optimized factor viii genes
CN105695616A (en) * 2016-04-22 2016-06-22 王冬国 Analysis marker for diagnosing thyroid cancer and application thereof
EP3548066A1 (en) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
TW201831521A (en) 2017-01-31 2018-09-01 美商生物化學醫療公司 Factor IX fusion proteins and methods of making and using same
FR3069540B1 (en) 2017-07-28 2019-09-13 Universite Claude Bernard Lyon 1 MODIFIED PROTEIN WITH IMPROVED HALF-LIFE
SG11202000764RA (en) 2017-08-09 2020-02-27 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof
MX2020003351A (en) 2017-09-27 2020-10-12 Sigilon Therapeutics Inc Methods, compositions, and implantable elements comprising active cells.
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
TW202014181A (en) 2018-04-04 2020-04-16 美商希吉隆醫療公司 Implantable particles and related methods
US20210145889A1 (en) 2018-04-04 2021-05-20 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
AU2019270184A1 (en) 2018-05-18 2020-11-26 Bioverativ Therapeutics Inc. Methods of treating hemophilia A
MX2021001599A (en) 2018-08-09 2021-07-02 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof for non-viral gene therapy.
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
UY38389A (en) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc IMPLANTABLE DEVICES FOR CELLULAR THERAPY AND RELATED METHODS
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
KR20220009389A (en) 2019-04-17 2022-01-24 코디악 바이오사이언시즈, 인크. Composition of exosomes and AAV
WO2021154414A2 (en) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides
CA3209399A1 (en) 2021-02-24 2022-09-01 Michael Thomas Pace System and method for a digitally beamformed phased array feed
WO2024081310A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
WO2024081309A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2638643B1 (en) * 1988-11-09 1991-04-12 Transgene Sa DNA SEQUENCE ENCODING HUMAN FACTOR IX OR AN ANALOGUE PROTEIN, EXPRESSION VECTOR, TRANSFORMED CELLS, PROCESS FOR PREPARING FACTOR IX, AND PRODUCTS OBTAINED THEREFROM
US6531298B2 (en) * 1997-07-21 2003-03-11 The University Of North Carolina At Chapel Hill Factor IX antihemophilic factor with increased clotting activity
WO2003020764A2 (en) * 2001-09-04 2003-03-13 Merck Patent Gmbh Modified factor ix
MXPA05010846A (en) * 2003-04-09 2006-03-30 Nektar Therapeutics Hemophilia treatment by inhalation of coagulation factors.
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
AU2004296860B2 (en) * 2003-12-03 2010-04-22 Novo Nordisk A/S Glycopegylated factor IX
EP2084274A2 (en) * 2006-06-19 2009-08-05 Nautilus Technology LLC Modified coagulation factor ix polypeptides and use thereof for treatment
US7700734B2 (en) * 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof

Also Published As

Publication number Publication date
RU2010146387A (en) 2012-05-27
ECSP10010551A (en) 2010-11-30
CN102083856A (en) 2011-06-01
DOP2010000311A (en) 2011-02-28
CR11737A (en) 2011-02-07
EP2288622A2 (en) 2011-03-02
CA2721683A1 (en) 2009-11-12
WO2009137254A3 (en) 2010-01-14
IL208718A0 (en) 2010-12-30
CO6311000A2 (en) 2011-08-22
WO2009137254A2 (en) 2009-11-12
MX2010011345A (en) 2011-02-23
JP2011517951A (en) 2011-06-23
EP2288622A4 (en) 2012-04-18
KR20110005862A (en) 2011-01-19
BRPI0910702A2 (en) 2016-07-05
SG189790A1 (en) 2013-05-31
AU2009244633A1 (en) 2009-11-12

Similar Documents

Publication Publication Date Title
SV2010003704A (en) MODIFIED POLIPEPTIDES OF FACTOR IX AND USES OF THE SAME
DOP2012000030A (en) MODIFIED FACTOR IX POLIPEPTIDES AND USES OF THE SAME
SV2009003393A (en) FACTOR POLIPEPTIDES VII MODIFICATIONS AND USES OF THE SAME
CR20140512A (en) DEVICES AND METHODS FOR THE MANUFACTURE OF IMPLANT COMPONENT ADDITIVES
GT201400166A (en) SYNTHETIC APELINE MIMETICS FOR THE CARDIAC INSUFFICIENCY TREATMENT
CO6331368A2 (en) MODIFIED POLIPEPTIDE FACTORS VII (FVII)
CY1116424T1 (en) ADENINIS PRODUCTION AS RISK RISK
CL2009000393A1 (en) Pharmaceutical composition comprising a) an activatable pharmaceutical agent, b) a plasmonic active agent; Useful for the treatment of cell proliferation disorders.
ECSP12012024A (en) COMBINED THERAPY FOR CANCER TREATMENT AND RELATED DIAGNOSTIC TESTS
UY34566A (en) 1,4? DIHYDROPIRIMIDINES 4.4? DISUSTITUTED AND ITS USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
CL2010001160A1 (en) Compounds derived from 3,8-diazabicyclo [4.2.0] octane and 3,6-diazabicyclo [3.2.0] heptane; pharmaceutical composition; orexin reeptor modulators, useful in the treatment of insomnia.
CL2008001626A1 (en) Compounds derived from fused heterocycles, a pharmaceutical agent that comprises them and their use in the prophylaxis and treatment of cancer.
EA201270619A1 (en) USE OF BETANEHOL FOR THE TREATMENT OF XEROSTOMY
BR112013010834B1 (en) modified factor ix polypeptides and uses thereof
MX2015001083A (en) Modified factor x polypeptides and uses thereof.
UY34781A (en) MODULATORS OF THE COMPLEMENT ROUTE AND USES OF THE SAME
UY35703A (en) ANTIBODIES AGAINST THE INHIBITOR-1 OF THE PLASMINOGEN ACTIVATOR (PAI-1) AND USES OF THE SAME
UY29250A1 (en) CYTOTOXIC AGENTS UNDERSTANDING NEW TAXANES MODIFIED IN C-2.-
CR20110630A (en) CARBOXAMIDE COMPOUNDS AND ITS USE AS CALPAIN INHIBITORS
NI201000015A (en) BUPROPION BROMHYDRATE AND THERAPEUTIC APPLICATIONS
DOP2010000251A (en) EFFECTIVE PARAMYXOVIRUS AS ANTITUMORAL
CY1114880T1 (en) MGLU2 AGONISTS
BR112012015461A2 (en) modified somatotropin boviina polypeptides and their uses
CL2020000019A1 (en) Iiarn agents for the inhibition of alpha-enac expression and methods of use.
SV2010003734A (en) 4- (3-CHLORO-2-FLUOROANILINO) DIFUMARATE SALT -7 METOXI-6 - {[1- (N-METILCARBAMOILMETIL) PIPERIDIN-4-IL-] OXI} QUINAZOLINA